InMed Pharmaceuticals Inc. (INM) Stock Score, Valuation & Financial Research
InMed Pharmaceuticals Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for INM
InMed Pharmaceuticals Inc. currently has a Wall Street Score of 21/100. The stored market price is $1.28. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What InMed Pharmaceuticals Inc. does
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis
INM financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $1.28
- Market capitalization:
- $2.3M
- Revenue:
- $4.0M
- Net income:
- $-9.9M
- Free cash flow:
- $-7.8M
- Cash:
- $5.2M
- Total debt:
- $420K
- EPS:
- -8.36
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 23/100
What stands out
- Reported year-over-year revenue growth is -0.2%.
- Free cash flow is $-7.8M, showing cash burn in the current stored period.
- The balance sheet shows $5.2M of cash versus $420K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.3 points: INM increased 0.3 points because Revenue improved by 3.5 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research INM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.